Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Androclus Therapeutics has completed a phase II clinical trial of AT-001, a novel orally administered therapeutic candidate for the treatment of rheumatoid arthritis.
Subscribe to our email newsletter
The trial enrolled 160 patients with the disorder in 11 centers across the US. Patients in the AT-001 arm of the trial received 25mg of AT-001 daily for six months.
When compared with placebo, patients treated with AT-001 experienced an improvement in the signs and symptoms of rheumatoid arthritis such as swollen joints, tenderness, pain and mobility. The drug was also found to be safe and well tolerated.
“In essence, we re-educated the T cells to be tolerant of the dnaJP1 amino acid sequence, which would usually trigger inflammation in rheumatoid arthritis patients,” said lead investigator Dr Salvatore Albani, professor of medicine and pediatrics at the University of California. “Our drug leaves the patient’s natural immune responses intact. This differs profoundly from what is currently available to patients.”